Longboard Pharmaceuticals Inc

Longboard Pharmaceuticals — Investor Presentation (November 2023)

50 slides from Longboard Pharmaceuticals's investor presentation, Nov 29, 2023

  1. Slide 1: Corporate Presentation November 29, 2023

    Corporate Presentation November 29, 2023 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: our vision; commercial opportunities and analogs; our development approach and position to have best-in-class d

  3. Slide 3: Our Vision is Backed by 20+ Years of World Class GPCR Research

    Our Vision is Backed by 20+ Years of World Class GPCR Research Longboard Thesis Vision A world where devastating neurological conditions are no longer devastating 3 Longboard Pharmaceuticals Differentiated & innovative clinical approaches Relevant M&A analogs JAZZ - GW $7.2B PFE - ARNA $6.7B UCB - Z

  4. Slide 4: Longboard's Best-in-Class Product Candidates

    Longboard’s Best-in-Class Product Candidates * Through a License Agreement with Arena ** Through a Royalty Purchase Agreement with Arena Definitions: DEEs=developmental and epileptic encephalopathies; S1P = sphingosine 1-phosphate; PK=pharmacokinetics; PD=pharmacodynamics; EEG = electroencephalogram

  5. Slide 5: Developmental & Epileptic Encephalopathies (DEE) Landscape

    Developmental & Epileptic Encephalopathies (DEE) Landscape

  6. Slide 6: Impact of Developmental and Epileptic Encephalopathies (DEEs)

    DEEs commonly begin in infancy or childhood and are associated with frequent seizures of multiple different types, intellectual disability, and significant delay or regression. Decision-Making Tree for Therapeutics Impact of Developmental and Epileptic Encephalopathies (DEEs) No Yes Safety Burden Ef

  7. Slide 7: The prevalence of all Other DEEs could exceed the Approved 4 combined

    The prevalence of all "Other DEEs" could exceed the total of the “Approved 4” combined 4 DEE Syndromes Have Approved Therapies; 20+ Have None Sources: Dravet Syndrome Foundation, LGS Foundation Definitions: LGS = Lennox-Gastaut Syndrome, CDD = CDKL5 Deficiency Disorder, TSC = Tuberous Sclerosis Comp

  8. Slide 8: HCPs Report a Need for More Effective and Safer Anti-Seizure Medications

    HCPs Report a Need for More Effective and Safer Anti-Seizure Medications % Frustrated with Lack of Available New Treatment Options for DEE Type Among those who treat any patients with DEE type Mean # of Seizures Per Week Mean # of ASMs Per Patient Dravet 12 3.4 LGS 19 3.5 TSC 6 3.0 CDD 13 2.9 % Rate

  9. Slide 9: DEE Indications Represent a $6B Total US + EU Market Opportunity

    1) Longboard and third-party research 2022 – projections for 2040 for US + EU4/UK, 2) UCB Annual Report 2022, 3) Jazz Pharmaceuticals Annual Report 2022, 4) UCB press release dated January 9, 2023, 5) Jazz Corporate Overview August 2023 DEE Indications Represent a $6B Total US + EU Market Opportunit

  10. Slide 10: The Importance of 5-HT2C in Epilepsy

    The Importance of 5-HT2C in Epilepsy

  11. Slide 11: Brain Regions Involved in Multiple Types of Seizures

    LGS = Lennox Gastaut syndrome; DS = Dravet syndrome; SUDEP = sudden unexpected death in epilepsy Source: Lindquist et. al. 2023; Burke et. al. 2014; Bosco et. al. 2023; Created with BioRender.com Brain Regions Involved in Multiple Types of Seizures Dysfunction of the circuits involving the cortex (i

  12. Slide 12: 5-HT2C Receptors are Expressed in Seizure-Related Brain Regions

    Source: (1) The Human Protein Atlas; (2) NeuroSeq; (3) Massey et. al. 2021; (4) Simonsson et. al. 2022; (5) Blond et. al. 2023 5-HT2C Receptors are Expressed in Seizure-Related Brain Regions 5-HT2C receptor expression is restricted to the brain 5-HT2C receptors are highly expressed in the brainstem,

  13. Slide 13: Role of 5-HT2C Receptors in Epilepsy

    Sources: Gharedaghi MH et al., Exp Brain Res. 2014; Bagdy G et al., J Neurochemistry. 2007; Strac DS et al., Front Neurosci. 2016; Sourbron J et al., ACS Chem Neuroscience. 2016; Tecott LH et al, Nature. 1995; Upton N et al, Eur J Pharmacol. 1998; Orban G et al., CNS Neurosci Ther. 2014; Schoonjans

  14. Slide 14: 5-HT2 Evolution in Rare Epilepsies

    5-HT2 Evolution in Rare Epilepsies Designed & Being Dose-Optimized for DEEs Weight Loss Drug Repurposed for Dravet Compound FINTEPLA® (fenfluramine, ZX008) LP352 History Designed to be a next-generation selective 5-HT2C superagonist Dose optimization for DEEs BID formulation work ongoing, expected f

  15. Slide 15: LP352 First-in-Class 5-HT2C Superagonist with Next-Generation Selectivity

    LP352 First-in-Class 5-HT2C Superagonist with Next-Generation Selectivity, Being Dose-Optimized to Treat a Broad Range of DEEs Effectively and Safely

  16. Slide 16: The Potential of LP352

    The Potential of LP352 *Radioligand binding assays assessing >150 targets showed significant affinity only to 5-HT2C receptors ** Based on first two cohorts ***Composition of matter through 2036 with potential for PTE / PTA (2041) Definitions: PAH = pulmonary arterial hypertension; AEs = adverse eve

  17. Slide 17: LP352 Designed to be a Next-Generation 5-HT2C with Greater Selectivity

    LP352 Designed to be a Next-Generation 5-HT2C with Greater Selectivity and Specificity 1 Third party study previously commissioned by Arena, 2 BELVIQ FDA approved prescribing information 06/2012; Note: The above table is for illustrative purposes only and is not a head-to-head comparison. Difference

  18. Slide 18: LP352 Inhibited Seizure Activity in Multiple Preclinical Models

    LP352 Inhibited Seizure Activity in Multiple Preclinical Models Definitions: ASM = anti-seizure medication; MOA = mechanism of action Corneal Kindling Pentylenetetrazol (PTZ) (i.v.) Scn1aA1783V/WT Transgene scn1lab Transgene Ethyl ketopentenoate (EKP) Kainic acid (KA) Model Partial (focal) limbic se

  19. Slide 19: LP352 Phase 1 Results

    LP352 Ph 1 Results – Favorable Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Observed Randomized, double-blind, placebo-controlled, 4-part trial in healthy adult males and females (N=83) Single Ascending Dose & Single-Dose Food Effect (N=40) Multiple Ascending Dose & Dose Titration (N=

  20. Slide 20: LP352 102: Phase 1 PK/PD CNS Study in Adult Healthy Volunteers

    LP352 102: Ph 1 PK/PD CNS Study in Adult Healthy Volunteers Topline data 28 Days Screening Period Day 25 Follow-up Up-Titration Days 1-2 Maintenance* Days 3-11 (target treatment Taper Down Day 11 (start taper after AM dose) Additional Cohorts Ongoing Cohort 1 (n=10) 6 mg TID Cohort 2 (n=10) 12 mg TI

  21. Slide 21: Steady State Plasma & CSF Concentrations for LP352

    Steady State Plasma & CSF Concentrations for LP352 (6mg & 12mg) *Topline data Ki Ki 12 mg TID Exceeded Ki Value for 5-HT2C Activity throughout Dosing Interval* LP352 selectivity may limit off-target effects associated with currently available non-selective ASMs

  22. Slide 22: Avoiding Drug-Drug Interactions in Polypharmacy Patients

    Cerny (2016) Drug Metabolism and Disposition 44:1246 *From Longboard HCP Survey 2023 Given the common nature of complex polypharmacy in patients with DEEs, avoiding DDIs is of particular importance Many ASMs are affected by CYP enzyme inhibitors, notably CYP2D6 (fenfluramine, carbamazepine), CYP3A4

  23. Slide 23: LP352 Ph 1b/2a PACIFIC study in patients with DEEs

    6 mg 9 mg 12 mg Participant remains on 6, 9 or 12 mg based on tolerability during up-titration 5 Wks Screening Period 30 Days Follow-up Period Randomization & Up-Titration Days 1-15 Maintenance* Days 16-75 Down- Titration Days 76- 80/90** LP352 Ph 1b/2a PACIFIC study in patients with DEEs * Maintena

  24. Slide 24: PACIFIC Study Enrollment Summary

    PACIFIC Study Enrollment Summary 52 Participants randomized Diagnosis* Vast majority of eligible participants who complete PACIFIC expected to enter Open-Label Extension 100% have entered to date** 42 US 10 AUS Adult/Pediatric participants Range: 12-55 Mean: 24.2 / Median: 23.0 40 Adult (18+) 12 Ped

  25. Slide 25: Seizure Reduction for Approved Drugs in DEEs

    1. Lagae, et al The Lancet 2019; 2. Knupp, et al JAMA Neurology 2022; 3. Knight,et al, The Lancet Neurology 2022; 4. Epidiolex HCP website Dravet & LGS & TSC Seizure Reduction for Approved Drugs in DEEs  FEN 0.2mg/kg  FEN 0.7mg/kg  Ganaxolone  Cannabidiol 10mg/kg  Cannabidiol 20mg/kg  Cannabid

  26. Slide 26: Key Areas of Focus in PACIFIC Topline Readout

    Key Areas of Focus in PACIFIC Topline Readout Seizure Reduction Clinically meaningful seizure reductions across the DEE landscape and consistent with approved treatments Safety Favorable safety & tolerability in line with previous Longboard studies to date OLE Participation Vast majority of eligible

  27. Slide 27: Commercial Opportunity for LP352

    Commercial Opportunity for LP352

  28. Slide 28: Multiple Potential Ways to Win

    Multiple Potential “Ways to Win” Capture market share in “Approved 4” with best-in-class profile (safety, efficacy, burden) Broaden market in “Approved 4” DEE’s with preferred safety and burden profile $6B Total Addressable Market

  29. Slide 29: Quantitative HCP Research

    Quantitative HCP Research 100 Physicians Objective: Validating Unmet Needs And LP352 Potential Criteria: Board Certified HCPs specializing in Neurology or Epileptology Treat at least 20 patients with DEEs in the past 12 months Familiar with Fintepla and Epidiolex Note: Most participants have some cl

  30. Slide 30: DEE Types Treated in the Past 12 Months

    DEE Types Treated in the Past 12 Months Total Respondents DEE Type Treated in Past 12 Months Total Respondents Nearly All HCPs Treat Patients with the “Approved 4” Longboard and third-party market research analysis

  31. Slide 31: HCPs Evaluate ASMs by Balancing Efficacy, Safety & Burden

    Influence on ASM Decisions When allocating 100 points across factors If I see a patient with epilepsy and give them enough valium, they’ll be seizure free, but then they'll be sleeping all day. That’s not quality of life. So, we must find the cocktail that gives them the best seizure control with th

  32. Slide 32: Fintepla Performance on Most Important Criteria

    The clinical trial in Dravet was amazing, really impressive efficacy. I would say Fintepla is comparable to other medications in reality. Now these are very difficult patients so it makes sense, but most people would say Fintepla is not as robust in its efficacy.” – Epileptologist, Primarily Pediatr

  33. Slide 33: Top Reasons Why Unlikely to Prescribe Fintepla

    Top Reasons Why Unlikely to Prescribe Fintepla* Mean % Caregivers Decline Fintepla Despite HCP Recommendation *Among those who don’t currently or are unlikely to prescribe Fintepla Fintepla Safety & Burden are Hard to Overcome; Physicians Unlikely to Recommend and Caregivers Decline Somewhat Regular

  34. Slide 34: Top Reasons for Prescribing LP352 Over Fintepla

    Top Reasons for Prescribing LP352 Sampled Product Profile Over Fintepla* HCPs Prefer LP352* Over Fintepla and Are More Likely to Prescribe it Because of the Superior Safety Profile *Those who would prescribe LP352 sampled product profile over Fintepla HCPs prefer LP352* mainly because of the superio

  35. Slide 35: Reality of the Treatment Paradigm: Balancing Safety, Efficacy and Burden

    Reality of the Treatment Paradigm: Balancing of Safety, Efficacy and Burden Polytherapy Approach: DEE patients are highly refractory and on an average of 3.5 medications simultaneously The combination of these criteria impact utilization AND FINTEPLA is re-assessed every six months No Yes Safety Bur

  36. Slide 36: Commercial Opportunity for Broad DEE Indication

    Commercial Opportunity for Broad DEE Indication

  37. Slide 37: Multiple Potential Ways to Win

    Multiple Potential “Ways to Win” $6B Total Addressable Market Capture market share in “Approved 4” with best-in-class profile (safety, efficacy, burden) Broaden market in “Approved 4” DEE’s with preferred safety and burden profile Expand market to address significant unmet need across “Other DEE” pa

  38. Slide 38: Nearly All HCPs Treat Patients with All DEE Diagnoses

    Nearly All HCPs Treat Patients with All DEE Diagnoses; Collectively, the Number of “Other DEEs” is Significant DEE Types Treated in the Past 12 Months Percent of Patients with DEE Type Longboard and third-party market research analysis

  39. Slide 39: Unmet Needs for Patients with Other DEEs

    Unmet Needs for Patients with Other DEEs Among those who treat patients with other DEEs (not “Approved 4”) HCPs Report a Need for More Effective and Safer Anti-Seizure Medications for Other DEEs Mean # of Seizures Per Week Mean # of ASMs Per Patient Dravet 12 3.4 LGS 19 3.5 TSC 6 3.0 CDD 13 2.9 Othe

  40. Slide 40: HCPs Prefer LP352 with a Broad DEE Indication

    HCPs Prefer LP352 with a Broad DEE Indication, and Anticipate This Will Positively Impact DEE Patients’ Treatment Options 6-Very strong preference for broad DEE indication 5- 4- 3- 2- 1-Very strong preference of indication specific to Dravet, LGS, TSC, CDD 7-Significant positive impact 6- 5- 4-No im

  41. Slide 41: LP659 Centrally Acting, Highly Selective S1P Receptor Modulator

    LP659 Centrally Acting, Highly Selective Sphingosine-1-Phosphate (S1P) Receptor Modulator Targeting Multiple Neurological Diseases

  42. Slide 42: LP659 Potential Best-in-Class S1P Receptor Modulator

    LP659 Potential Best-in-Class S1P Receptor Modulator with Broad Applicability STRONG SCIENTIFIC RATIONALE COMMERCIALLY ATTRACTIVE S1P receptor modulators have generated billions of dollars of revenues in CNS indications Designed to address multiple neurological disorders Opportunity for market leade

  43. Slide 43: S1PR1 Modulation Selectively Reduces Migration of Lymphocytes

    S1PR1 Modulation Selectively Reduces Migration of Lymphocytes From Lymph Nodes Functionally antagonizes S1PR1 by inducing receptor internalization and degradation, disrupting normal lymphocyte subset egress Decreases release of inflammatory cytokines and reduce organ/tissue damage Maintains immune s

  44. Slide 44: LP659 Designed to be a Next Generation Centrally-Acting S1PR1 Agonist

    LP659 Designed to be a Next Generation Centrally-Acting S1PR1 Agonist with Greater Selectivity and Internalization-Biased Signaling LP659 selectivity may limit off-target effects associated with currently approved S1P receptor modulators Greatest selectivity towards S1PR1 over S1PR5 Most potent at S

  45. Slide 45: Modulation of Immune Tolerance Drives Efficacy by LP659

    Modulation of Immune Tolerance Drives Efficacy by LP659 LP659 potency in vivo parallels T and B cell lowering potential Proportion of Tregs over total CD3+ cells is significantly increased by LP659 No significant effects on NK and monocyte frequencies Internal data on file

  46. Slide 46: LP659 Ameliorated Disease Phenotypes in Multiple Preclinical Models

    LP659 Ameliorated Disease Phenotypes in Multiple Preclinical Models Disease / MoA Autoimmune, CNS involvement Autoimmune, CNS involvement Autoimmune, PNS involvement Autoimmune, PNS involvement Neuro Degenerative Model Induced Induced Induced Induced Genetic Species Rat Mouse Rat Rat Human iPSC Dosi

  47. Slide 47: LP659: Phase 1 Single-Ascending Dose (SAD) Study Objectives

    LP659: Phase 1 Single-Ascending Dose (SAD) Study Objectives First-In-Human, Randomized, Double Blind, Placebo Controlled, SAD Study to Assess the Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of LP659 in up to 48 Adult Healthy Volunteers Key Study Objectives: Assess the safety and tolera

  48. Slide 48: Longboard Indication Assessment Process

    Longboard Indication Assessment Process Scientific Rationale Commercial & Development Criteria Etiology Pathophysiology Approved SoC Preclinical Studies Patient Advocacy & Recruitment Degree of Unmet Need Speed of Clinical Development Clinical Trial Feasibility Competitive Headroom Pricing Potential

  49. Slide 49: Financial Summary & Upcoming Milestones

    Financial Summary* & Upcoming Milestones Multiple clinical and preclinical studies in process to further support the development of LP352 & LP659 Cash, Cash Equivalents & Investments $56.0 million As of September 30, 2023 Shares Outstanding 23.9 million As of October 31, 2023 Third Quarter 2023 Oper

  50. Slide 50: Thank you

    Thank you Nasdaq: LBPH IR@longboardpharma.com

Longboard Pharmaceuticals — Investor Presentation (November 2023) on 6ix